Related Experiment Video

Updated: Sep 29, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma

Rovingaile Kriska M Ponce1, Nicholas J Thomas1, Nam Q Bui2

  • 1Department of Medicine, UCSF, San Francisco, California, USA.

JCI Insight
|March 22, 2022
PubMed

Insights

CIC-DUX4 sarcomas are aggressive cancers. Targeting the WEE1 protein kinase inhibits cancer cell growth by inducing DNA damage and apoptosis, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • CIC-DUX4 rearrangements characterize aggressive, chemotherapy-insensitive undifferentiated sarcomas.
  • The CIC-DUX4 fusion oncogene upregulates cell cycle and DNA replication genes, leading to CCNE1 overexpression.
  • This CCNE1 upregulation causes a G1/S transition defect, creating a dependency on the G2/M cell cycle checkpoint for survival.

Purpose of the Study:

  • To identify therapeutic vulnerabilities in CIC-DUX4 sarcomas.
  • To investigate the role of the G2/M cell cycle checkpoint in CIC-DUX4 sarcoma survival.
  • To evaluate WEE1 as a potential therapeutic target.

Main Methods:

  • Integrative transcriptional and kinase activity screening of patient-derived CIC-DUX4 sarcoma specimens.
  • In vitro and in vivo genetic and pharmacologic inhibition of WEE1.
  • Assessment of DNA damage, mitotic entry, apoptosis, and cell viability.

Main Results:

  • CIC-DUX4 sarcomas exhibit dependency on the G2/M checkpoint regulator WEE1 for survival.
  • WEE1 activity in these sarcomas limits DNA damage and prevents unscheduled mitotic entry.
  • WEE1 inhibition (genetic or pharmacologic) induced rapid, DNA damage-associated apoptosis in patient-derived CIC-DUX4 sarcomas, both in vitro and in vivo.

Conclusions:

  • WEE1 is a critical adaptive survival mechanism in CIC-DUX4 sarcomas.
  • Targeting WEE1 represents a promising therapeutic strategy for CIC-DUX4 sarcomas.
  • WEE1 inhibition effectively induces apoptosis in these aggressive cancers.
Keywords:
CancerOncology

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.8K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.7K